中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
2期
252-255
,共4页
胃癌%微小RNA%奥沙利铂
胃癌%微小RNA%奧沙利鉑
위암%미소RNA%오사리박
Gastric cancer%MicroRNA%Oxaliplatin
目的 探讨微小RNA-21(miR-21)在胃癌组织中表达的意义,并评估miR-21与含奥沙利铂的二药联合方案治疗晚期胃癌患者临床预后的相关性.方法 入组患者均为不能手术或手术后复发的转移性胃癌.化疗方案为奥沙利铂联合替吉奥(S-(1))或奥沙利铂联合去氧氟脲苷.从52例福马林固定后石蜡包埋(FFPE)的胃癌组织样本中筛选鉴定出可以作为预后标志物的miRNA.从胃癌患者FFPE肿瘤组织样本和正常胃组织中分别提取出总RNA,应用荧光定量聚合酶链反应(FQ-PCR)定量分析miRNA(包括let-7g、miR-200c、miR-140、miR-21、miR-192、miR-181b)表达水平,并分析其与胃癌患者预后的相关性.结果 胃癌组织中miR-21表达水平显著高于正常胃组织(5.43±7.95比1.00).多因素生存分析显示:miR-21高表达胃癌患者总生存期显著低于miR-21低表达患者,中位生存期分别为5.03(2.67 ～7.40)和8.74(6.58～10.89)个月,与miR-21低表达胃癌患者比较,其死亡风险比(HR)为8.11[95％可信区间(CI):2.47 ～26.59,P＜0.01]；2个疗程后疗效较好者生存期显著高于疗效较差者,疗效为部分缓解(PR)、稳定(SD)、进展(PD)的患者中位生存期分别为8.41(5.29 ～11.52)、10.57(5.68～15.47)和5.10(3.11 ～7.08)个月.相对于PR患者,SD、PD患者的HR分别为0.96(95％CI:0.36 ～2.54,P＞0.05)和6.65(95％ CI:2.08 ～21.24,P＜0.01).结论 胃癌组织中存在微小RNA异常表达,其中miR-21高表达与晚期胃癌不良预后显著相关.
目的 探討微小RNA-21(miR-21)在胃癌組織中錶達的意義,併評估miR-21與含奧沙利鉑的二藥聯閤方案治療晚期胃癌患者臨床預後的相關性.方法 入組患者均為不能手術或手術後複髮的轉移性胃癌.化療方案為奧沙利鉑聯閤替吉奧(S-(1))或奧沙利鉑聯閤去氧氟脲苷.從52例福馬林固定後石蠟包埋(FFPE)的胃癌組織樣本中篩選鑒定齣可以作為預後標誌物的miRNA.從胃癌患者FFPE腫瘤組織樣本和正常胃組織中分彆提取齣總RNA,應用熒光定量聚閤酶鏈反應(FQ-PCR)定量分析miRNA(包括let-7g、miR-200c、miR-140、miR-21、miR-192、miR-181b)錶達水平,併分析其與胃癌患者預後的相關性.結果 胃癌組織中miR-21錶達水平顯著高于正常胃組織(5.43±7.95比1.00).多因素生存分析顯示:miR-21高錶達胃癌患者總生存期顯著低于miR-21低錶達患者,中位生存期分彆為5.03(2.67 ～7.40)和8.74(6.58～10.89)箇月,與miR-21低錶達胃癌患者比較,其死亡風險比(HR)為8.11[95％可信區間(CI):2.47 ～26.59,P＜0.01]；2箇療程後療效較好者生存期顯著高于療效較差者,療效為部分緩解(PR)、穩定(SD)、進展(PD)的患者中位生存期分彆為8.41(5.29 ～11.52)、10.57(5.68～15.47)和5.10(3.11 ～7.08)箇月.相對于PR患者,SD、PD患者的HR分彆為0.96(95％CI:0.36 ～2.54,P＞0.05)和6.65(95％ CI:2.08 ～21.24,P＜0.01).結論 胃癌組織中存在微小RNA異常錶達,其中miR-21高錶達與晚期胃癌不良預後顯著相關.
목적 탐토미소RNA-21(miR-21)재위암조직중표체적의의,병평고miR-21여함오사리박적이약연합방안치료만기위암환자림상예후적상관성.방법 입조환자균위불능수술혹수술후복발적전이성위암.화료방안위오사리박연합체길오(S-(1))혹오사리박연합거양불뇨감.종52례복마림고정후석사포매(FFPE)적위암조직양본중사선감정출가이작위예후표지물적miRNA.종위암환자FFPE종류조직양본화정상위조직중분별제취출총RNA,응용형광정량취합매련반응(FQ-PCR)정량분석miRNA(포괄let-7g、miR-200c、miR-140、miR-21、miR-192、miR-181b)표체수평,병분석기여위암환자예후적상관성.결과 위암조직중miR-21표체수평현저고우정상위조직(5.43±7.95비1.00).다인소생존분석현시:miR-21고표체위암환자총생존기현저저우miR-21저표체환자,중위생존기분별위5.03(2.67 ～7.40)화8.74(6.58～10.89)개월,여miR-21저표체위암환자비교,기사망풍험비(HR)위8.11[95％가신구간(CI):2.47 ～26.59,P＜0.01]；2개료정후료효교호자생존기현저고우료효교차자,료효위부분완해(PR)、은정(SD)、진전(PD)적환자중위생존기분별위8.41(5.29 ～11.52)、10.57(5.68～15.47)화5.10(3.11 ～7.08)개월.상대우PR환자,SD、PD환자적HR분별위0.96(95％CI:0.36 ～2.54,P＞0.05)화6.65(95％ CI:2.08 ～21.24,P＜0.01).결론 위암조직중존재미소RNA이상표체,기중miR-21고표체여만기위암불량예후현저상관.
Objective To investigate the significance of microRNA-21 (miRNA-21,miR-21) expression in gastric cancer and assess the correlation between miRNA-21 and clinical outcome of the latestage gastric cancer patients treated with chemotherapy of allied two medicines containing Oxaliplatin.Methods Metastatic gastric cancer patients who are not candidates for curative surgery or recurred after operation were recruited for the trial.The patients were treated with S-1 plus i.v.with Oxaliplatin or Doxifluridine plus i.v.with Oxaliplatin.The expression of candidate miRNAs was quantified from fifty-two late stage gastric cancer formalin fixed paraffin-embedded (FFPE) specimens.Total RNAs were extracted from normal and gastric tumor specimens.The levels of miRNAs (including let-7g,miR-200c,miR-140,miR-21,miR-192 and miR-181b) were quantified using real time fluorescent quantitative polymerase chain reaction (FQ-PCR) expression analysis.In addition,we will further analyze its clnical significance in gastric cancer.Results The expression of miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues (5.43 ± 7.95 vs 1.00).Kaplan-Meier survival analysis revealed that high level of miR-21 expression was closely associated with poor overall survival (OS) for Oxaliplatin based regimens.The median OS of miR-21 low expression patient subgroup was 8.74(6.58-10.89) months,while was only 5.03(2.67-7.40) months for the high expression subgroup,patients with high miR-21 expression showed a significant increase in hazard ratio (HR) for death [HR =8.11,95 ％ confidence interval (CI):2.47-26.59,P ＜ 0.01].The efficacy after two cycles was also found to be significant variable in predicting OS,the median OS for patients with patial response (PR),stable disease (SD) and progressive diease (PD) were 8.41(5.29-11.52),10.57 (5.68-15.47) and 5.10(3.11-7.08) months respectively.Compared to patients with PR,the HR for death were 0.96 (95％ CI:0.36-2.54,P ＞ 0.05) and 6.65 (95％ CI:2.08-21.24,P ＜ 0.01) for patients with SD and PD.Conclusion Abnormal versions of microRNAs have been implicated in gastric cancer,and miR-21 holds great potential as prognostic biomarkers in late stage gastric cancer.
